Breast Cancer Outcomes Unit, BC Cancer Agency, Vancouver, British Columbia.
Curr Oncol. 2007 Dec;14(6):227-33. doi: 10.3747/co.2007.156.
In this study, we set out to determine the frequency and severity of anemia and the corrective interventions used during adjuvant chemotherapy for breast cancer.We conducted a retrospective electronic chart review of 702 patients who received adjuvant breast cancer chemotherapy at four BC Cancer Agency centres in 2002 and 2003. For these patients, we recorded the initial hemoglobin reading and the date of the first hemoglobin reading in the ranges 110-119 g/L, 100-109 g/L, 90-99 g/L, and <90 g/L. We also recorded any discussion about, or delivery of, interventions for anemia [transfusion, epoetin (epo) or both].Median age of the study population was 51 years, and it varied with chemotherapy type. Among the patients, 12% had a hemoglobin reading <120 g/L before the start of chemotherapy. Overall, the proportion of patients with at least one hemoglobin reading <120 g/L was 78%; <110 g/L, 54%; <100 g/L, 31%; and <90 g/L, 14%. Depending on chemotherapy type, a hemoglobin reading <100 g/L occurred in 5% to 54% of patients. Intervention rates increased as hemoglobin declined. For 99 patients with a hemoglobin reading <90 g/L, a discussion of anemia was documented in the treatment chart in 49% of cases, a transfusion was delivered in 23%, epo was used in 11%, and transfusion and epo were both delivered in 5%.Anemia was relatively common and varied with chemotherapy type. Documentation of a discussion of anemia occurred in fewer than 20% of the patients with a hemoglobin reading of 90-99 g/L and in only half the patients with a hemoglobin reading <90 g/L. Intervention rates were low at hemoglobin readings for which randomized trials have shown that intervention can improve quality of life.
在这项研究中,我们旨在确定乳腺癌辅助化疗期间贫血的频率和严重程度,以及所采用的纠正干预措施。我们对 2002 年和 2003 年在四个不列颠哥伦比亚癌症署中心接受辅助乳腺癌化疗的 702 例患者进行了回顾性电子病历审查。对于这些患者,我们记录了初始血红蛋白读数以及血红蛋白读数在 110-119g/L、100-109g/L、90-99g/L 和 <90g/L 范围内的首次血红蛋白读数日期。我们还记录了有关贫血干预措施(输血、促红细胞生成素(epo)或两者)的任何讨论或实施情况。研究人群的中位年龄为 51 岁,且因化疗类型而异。在这些患者中,有 12%在开始化疗前血红蛋白读数 <120g/L。总体而言,至少有一次血红蛋白读数 <120g/L 的患者比例为 78%;<110g/L,54%;<100g/L,31%;<90g/L,14%。根据化疗类型,血红蛋白读数 <100g/L 的患者比例为 5%至 54%。随着血红蛋白水平的下降,干预率增加。对于 99 例血红蛋白读数 <90g/L 的患者,在治疗图表中记录了 49%的病例有贫血讨论,23%的患者接受了输血,11%的患者使用了 epo,5%的患者同时接受了输血和 epo。贫血较为常见,且因化疗类型而异。血红蛋白读数在 90-99g/L 的患者中,有<20%的患者记录了贫血讨论,而血红蛋白读数 <90g/L 的患者中仅有一半记录了贫血讨论。在随机试验表明干预可以提高生活质量的血红蛋白读数时,干预率较低。